Evaluate Discovery
NEWSLETTER
Welcome to Evaluate Discovery, a round up of our most-read content this month.
Featured Webinar: Licence Drivers: Trends in Pharma Dealmaking
Tuesday, 1st October 3PM BST | 10AM EDT
Licensing deals are a critical part of the symbiotic relationship between Big Pharma and biotechs. Big players, many of whom are facing down huge losses through patent expiry, have to balance risk aversion with the need to strengthen pipelines. Meanwhile, biotech and smaller pharma companies must secure investment to get their assets to the next stage.
Register to sign up for Evaluate's Discovery newsletter, including the latest thought leadership & news.
Looking for more? Scroll down for more of our latest content on the hottest topics in pharma.
Welcome to Evaluate Discovery, a round up of our most-read content this month.
Have you downloaded your copy of the World Preview 2024 report?
Have you downloaded your copy of the World Preview 2024 report? It’s our annual dive into the latest forecasts for the pharma market and if you’ve not read it yet, you can find it here. Featuring expert analysts and tonnes of data, it’s a must-read for anyone who needs to understand the direction of the market, from key players to top pipeline projects.
E-BOOK
Billion Dollar Blueprint: The Journey to Blockbuster Status
Learn about the role that indications play, the typical timeline to reach blockbuster status, and the advantages of developing drugs internally versus outsourcing.
REPORT
Analysis: Which Pharma Companies are Making Their Money Work?
Our latest analysis reveals the spending patterns of the top 15 companies in 2023. Discover how they balance investment in R&D with strategic acquisitions and licensing deals to achieve the best results.
On-Demand Webinar
AI and ML in Pharma: Redefining the Forecasting Landscape
Join leading experts from J+D Forecasting as they shed light on the transformative potential of AI and ML in pharmaceutical forecasting, enabling more precise predictions, improved decision-making, and strategic guidance for the industry.
Flyer
Evaluate for Commercial Opportunity Assessment
Use Evaluate to access the breadth and depth of insights you need to prioritise opportunities and amplify commercial success. We combine company financials and profiles, product attributes, consensus forecasts, and market knowledge to help you take the right products to the right market in the right way.
Blog
Who’s winning in the battle for efficient capital deployment?
Over the last 10 years, large pharma companies have spent an average of $120bn across R&D and business development investments. Which companies have been most effective at deploying capital across M&A, licensing and R&D?
BLOG
2024 Dealmaking: What’s the Score?
Our BD&L webinar takes place tomorrow. For a sneak peak at what our expert panel will be discussing, why not check out the blog by Ben Folwell?
upcoming events
Bio Europe
November 4 – 6, 2024 Stockholm , Sweden
Join Evaluate at BIO Europe and connect with delegates spanning the global life science ecosystem to propel dealmaking and innovation.
Come visit Booth #82 and find out how Evaluate provides insights and guidance for both big pharmaceutical companies and biotechs on how to navigate licensing deals and maximise the success of their partnerships.
